UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450

Xenobiotica, 2018-06, Vol.48 (6), p.555-564

2018

Link zum Volltext

Verfügbarkeit prüfen

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Journal of clinical oncology, 2002-05, Vol.20 (9), p.2240-2250

2002

Link zum Volltext

Verfügbarkeit prüfen

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Journal of clinical oncology, 2002-09, Vol.20 (18), p.3815-3825

2002

Link zum Volltext

Verfügbarkeit prüfen

In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib

Xenobiotica, 2017-10, Vol.47 (10), p.903-915

2017

Link zum Volltext

Verfügbarkeit prüfen

Single-dose clinical pharmacokinetic studies of gefitinib

Clinical pharmacokinetics, 2005-01, Vol.44 (11), p.1165-1177

2005

Link zum Volltext

Verfügbarkeit prüfen

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics

Clinical pharmacokinetics, 2006-01, Vol.45 (6), p.633-644

2006

Link zum Volltext

Verfügbarkeit prüfen

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

Cancer chemotherapy and pharmacology, 2011-12, Vol.68 (6), p.1485-1495

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

Clinical pharmacokinetics, 2005-01, Vol.44 (10), p.1067-1081

2005

Link zum Volltext

Verfügbarkeit prüfen

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man

Xenobiotica, 2014-12, Vol.44 (12), p.1083-1098

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

Clinical pharmacokinetics, 2001, Vol.40 (4), p.297-306

2001

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

The New England journal of medicine, 2009-07, Vol.361 (2), p.123-134

2009

Link zum Volltext

Verfügbarkeit prüfen

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

Cancer chemotherapy and pharmacology, 2007-09, Vol.60 (4), p.479-488

2007

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

Investigational new drugs, 2013-08, Vol.31 (4), p.949-958

2013

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours

British journal of cancer, 2022-07, Vol.127 (1), p.92-101

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of the Novel Biologically Targeted Anticancer Agent Gefitinib

Clinical cancer research, 2004-07, Vol.10 (14), p.4607-4613

2004

Link zum Volltext

Verfügbarkeit prüfen

Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies

Cancer chemotherapy and pharmacology, 2016-10, Vol.78 (4), p.775-784

2016

Link zum Volltext

Verfügbarkeit prüfen

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

Cancer chemotherapy and pharmacology, 2015-10, Vol.76 (4), p.723-729

2015

Link zum Volltext

Verfügbarkeit prüfen

DDIS-19. OLAPARIB PENETRATES TUMOUR MARGINS AS WELL AS CONTRAST ENHANCING REGIONS OF GLIOBLASTOMA AT THERAPEUTIC LEVELS: INTERIM RESULTS OF THE OPARATIC TRIAL NCT01390571

Neuro-oncology (Charlottesville, Va.), 2016-11, Vol.18 (suppl_6), p.vi51-vi51

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

Advances in therapy, 2015-06, Vol.32 (6), p.510-522

2015

Link zum Volltext

Verfügbarkeit prüfen

Olaparib does not cause clinically relevant QT/QT^sub c^ interval prolongation in patients with advanced solid tumours: results from two phase I studies

Cancer chemotherapy and pharmacology, 2016-10, Vol.78 (4), p.775

2016

Link zum Volltext

Verfügbarkeit prüfen

Olaparib does not cause clinically relevant QT/QT sub(c) interval prolongation in patients with advanced solid tumours: results from two phase I studies

Cancer chemotherapy and pharmacology, 2016-10, Vol.78 (4), p.775-784

2016

Link zum Volltext

Verfügbarkeit prüfen

Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy

Clinical cancer research, 2004-07, Vol.10 (14), p.4607-4613

2004

Link zum Volltext

Verfügbarkeit prüfen

Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2599-2599

2014

Link zum Volltext

Verfügbarkeit prüfen

Results of stage 1 of the oparatic trial: A phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2025-2025

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(34)
Webseiten
(1)

Sprache

Englisch
(35)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Male
(18)
Middle Aged
(18)
Pharmacology & Pharmacy
(17)
Female
(15)
Adult
(14)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Oncology
(14)
Pharmacology. Drug Treatments
(13)
Antineoplastic Agents - Pharmacokinetics
(12)
Aged
(11)
Antineoplastic Agents
(11)
Quinazolines - Pharmacokinetics
(10)
Dose-Response Relationship, Drug
(8)
Neoplasms - Drug Therapy
(8)
Antineoplastic Agents - Therapeutic Use
(7)
Olaparib
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib

Single-dose clinical pharmacokinetic studies of gefitinib

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours

Development of the Novel Biologically Targeted Anticancer Agent Gefitinib

Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

DDIS-19. OLAPARIB PENETRATES TUMOUR MARGINS AS WELL AS CONTRAST ENHANCING REGIONS OF GLIOBLASTOMA AT THERAPEUTIC LEVELS: INTERIM RESULTS OF THE OPARATIC TRIAL NCT01390571

Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies

Olaparib does not cause clinically relevant QT/QT^sub c^ interval prolongation in patients with advanced solid tumours: results from two phase I studies

Olaparib does not cause clinically relevant QT/QT sub(c) interval prolongation in patients with advanced solid tumours: results from two phase I studies

Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy

Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation

Results of stage 1 of the oparatic trial: A phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma

Suchergebnisse filtern